FREESTOM Tablets Gastro-Resistant 20 Milligram

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

PANTOPRAZOLE SODIUM SESQUIHYDRATE

Available from:

Sanofi-Aventis Ireland Limited

Dosage:

20 Milligram

Pharmaceutical form:

Tablets Gastro-Resistant

Authorization date:

2011-07-08

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Freestom 20 mg gastro-resistant tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 20 mg pantoprazole (as sodium sesquihydrate).
Excipient: 38.425 mg Maltitol and 0.345 mg Lecithin (derived from soya oil) (see section 4.4)
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Gastro-resistant tablet
Yellow, oval tablet.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 20 mg pantoprazole (one tablet) per day.
It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Once complete
relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without
consulting a doctor.
If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a
doctor.
_Special populations_
No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function.
_Paediatric use_
_PANTOPRAZOLE _is not recommended for use in children and adolescents below 18 years of age due to insufficient
data on safety and efficacy.
Method of administration
_PANTOPRAZOLE _20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole
with liquid before a meal.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance, substituted benzimidazoles, lecithin (derived from soya oil) or to any of the
excipients.
Co-administration with atazanavir (see section 4.5).
IRISH MEDICINES BOARD
_______________________________________________________________________________
                                
                                Read the complete document